A new 4R-specific tau tracer, [18F]CBD-2115, has been developed by Lindberg et al. on 2021 which showed higher affinity for PSP-specific 4R tau compared to flortaucipir in preclinical evaluations (248). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.